Imaginostics
Imaginostics is a longevity and health tech startup changing the paradigm of medical imaging by delivering quantitative biomarkers for precision medicine. The proprietary magnetic resonance (MR) imaging technology overcomes the qualitative limitations of traditional MRI and enables the quantification of brain abnormalities. Imaginostics’ software is readily on preclinical and clinical MRI scanners and is compatible with existing hardware. A single scan generates quantitative maps of vascular microstructure, function, and leakage, where other technologies are limited in statistical significance.
** Currently fundraising **
Imaginostics on the Move
-
Finished preclinical studies and are running a pivotal clinical study starting Fall 2022 at Brigham and Women’s Hospital in Boston. The study will test (a) the ability for early detection of dementia in patients with mild cognitive impairment, and (b) the ability to quantify vascular abnormality in vascular dementia.
-
Imaginostics raised its first $1M from angel clinicians. In this round, Imaginostics has raised over $2.5M, including two non-dilutive grants from the National Institutes of Health (NIH) and $725k in private equity funding from the Alzheimer's Drug Discovery Foundation (ADDF). We are fundraising $1M to complete runway for our 18-month strategic plan before reaching Series A, to be partly backed by the ADDF.
